Harvard Bioscience, Inc. HBIO PHARMA
Company Overview
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $86.55M (-8.1% YoY); net profit $-56.70M.
- Trailing 12 Months Year-on-year growth — revenue +11.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.06% |
| 1 Year: | 11.10% |
Stock Price Performance
| 1 Year: | +59.00% |
| 6 Months: | +62.24% |
| 3 Months: | +32.28% |
| 1 Month: | +22.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HBIO Harvard Bioscience, Inc. PHARMA | 7.95 | -3.46 | $36.19M | 0.00% | -83.60% | -89.95% | 0.06% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.76M | 31.52M | 28.64M | 33.86M | 28.20M | 29.58M | 27.42M | 30.97M | 23.77M | 23.31M | 24.04M | 26.99M | 29.20M | 29.66M | 28.78M | 29.21M | 26.92M | 29.98M | 28.76M | 25.36M | 24.51M | 23.10M | 21.97M | 21.77M | 20.45M | 20.59M | 20.75M |
| Gross Profit | 13.86M | 11.48M | 12.60M | 11.73M | 12.92M | 12.95M | 11.68M | 11.69M | 12.11M | 9.58M | 9.07M | 9.50M | 11.02M | 13.27M | 15.36M | 15.82M | 18.74M | 16.15M | 15.96M | 14.98M | 17.23M | 12.98M | 13.86M | 13.49M | 15.43M | 16.35M | 16.31M | 16.18M | 16.64M | 12.17M | 18.35M | 16.67M | 14.73M | 14.77M | 13.22M | 12.77M | 12.18M | 11.53M | 12.02M | 12.24M |
| Operating Income | 2.12M | -1.15M | 99.00K | -775.00K | 113.00K | -221.00K | -840.00K | -813.00K | -1.12M | -350.00K | -269.00K | -390.00K | 374.00K | -1.27M | -382.00K | 890.00K | 1.74M | -120.00K | 228.00K | -1.36M | 1.63M | -3.27M | 556.00K | 182.00K | -239.00K | 58.00K | 548.00K | -6.71M | 4.00M | -3.76M | 1.75M | 796.00K | -933.00K | -2.28M | -2.07M | -1.87M | -49.67M | -819.00K | 197.00K | -1.17M |
| Net Income | -19.00K | -1.40M | 349.00K | -847.00K | -17.14M | -636.00K | -713.00K | -1.64M | -1.32M | -1.07M | -381.00K | -417.00K | 999.00K | -4.06M | -1.46M | -256.00K | 2.86M | -2.37M | -247.00K | -2.62M | 550.00K | -4.52M | -1.58M | -1.10M | -669.00K | -410.00K | -170.00K | -6.88M | 2.44M | -3.40M | 622.00K | -980.00K | -1.24M | -4.69M | -2.93M | -4.80M | -50.34M | -2.28M | -1.23M | -3.42M |
| Diluted EPS | 0.00 | -0.04 | 0.01 | -0.02 | -0.51 | -0.02 | -0.02 | -0.05 | -0.04 | -0.03 | -0.01 | -0.01 | 0.03 | -0.11 | -0.04 | -0.01 | 0.08 | -0.06 | -0.01 | -0.07 | 0.02 | -0.12 | -0.04 | - | - | -0.01 | - | -0.17 | 0.06 | -0.08 | 0.01 | -0.02 | -0.03 | -0.11 | -0.07 | -0.11 | -11.42 | -0.05 | -0.03 | -0.77 |
| R&D Expense | - | 1.75M | 1.71M | 1.43M | - | 1.43M | 1.50M | 1.31M | - | 1.28M | 1.30M | 1.54M | - | 2.40M | 2.76M | 2.78M | - | 2.73M | 2.77M | 2.56M | - | 2.49M | 1.90M | 1.95M | 2.49M | 2.70M | 2.66M | 3.22M | 3.50M | 2.76M | 2.90M | 2.96M | 2.76M | 2.88M | 2.63M | 2.57M | 2.32M | 2.19M | 2.13M | 2.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.77M | 108.18M | 108.86M | 111.17M | 105.17M | 108.66M | 108.66M | 104.52M | 77.41M | 120.77M | 116.18M | 102.10M | 118.90M | 113.33M | 112.25M | 94.14M | 86.55M |
| Gross Profit | 41.68M | 51.81M | 50.19M | 52.34M | 47.70M | 49.34M | 48.72M | 48.41M | 39.17M | 63.18M | 64.32M | 58.04M | 67.65M | 60.82M | 66.07M | 54.77M | 49.91M |
| Operating Income | 8.05M | 10.22M | 8.40M | 7.83M | 1.54M | 6.62M | -1.71M | -3.00M | -635.00K | 984.00K | 377.00K | 221.00K | 2.07M | -6.93M | 1.89M | -6.21M | -48.58M |
| Net Income | 7.23M | 19.02M | 3.81M | 2.37M | -1.83M | 2.35M | -19.04M | -4.31M | -865.00K | -2.92M | -4.69M | -7.81M | -288.00K | -9.52M | -3.42M | -12.40M | -56.70M |
| Diluted EPS | 0.24 | 0.65 | 0.13 | 0.08 | -0.06 | 0.07 | -0.57 | -0.13 | -0.02 | -0.08 | -0.12 | - | - | -0.23 | -0.08 | -0.28 | -1.28 |
| R&D Expense | 4.40M | 4.67M | 3.87M | 4.34M | 4.15M | 4.88M | 6.42M | 5.39M | 5.64M | 10.99M | 10.71M | 8.69M | 10.80M | 12.33M | 11.76M | 10.41M | 8.82M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 124.80M | 126.63M | 133.48M | 135.46M | 135.92M | 120.05M | 107.77M | 109.35M | - | 168.61M | 164.87M | 156.25M | 162.34M | 145.36M | 137.37M | 126.64M | 80.07M |
| Total Equity | 66.72M | 75.26M | 90.25M | 95.50M | 104.21M | 94.48M | 95.47M | 77.60M | 72.20M | 80.90M | - | 82.72M | 81.69M | 76.68M | 83.40M | 72.22M | 73.07M | 63.34M | 13.73M |
| Cash & Equivalents | 13.70M | 16.59M | 19.70M | 17.92M | 20.68M | 25.77M | 14.13M | 6.74M | 5.60M | 5.19M | - | 8.17M | 8.34M | 8.32M | 7.82M | 4.51M | 4.28M | 4.11M | 8.61M |
| Long Term Debt | - | - | 18.01M | 16.30M | 12.95M | 19.75M | 16.45M | 16.37M | 11.37M | 8.98M | 11.90M | 54.81M | 46.92M | 46.29M | 45.09M | 43.01M | 30.70M | 0 | 35.87M |
| Total Liabilities | - | - | 34.55M | 31.14M | 29.27M | 40.98M | 40.45M | 42.45M | 35.57M | 28.45M | - | 85.89M | 83.18M | 79.57M | 78.94M | 73.14M | 64.29M | 63.30M | 66.34M |
| Current Liabilities | - | - | 11.30M | 9.56M | 9.90M | 16.09M | 18.10M | 19.32M | 14.60M | 14.04M | - | 25.49M | 25.31M | 21.05M | 25.32M | 23.25M | 26.54M | 54.96M | 21.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 16.51M | 12.29M | 6.65M | 8.06M | 4.06M | 4.35M | 705.00K | 5.38M | 1.06M | 2.88M | 8.04M | 9.33M | 1.26M | 1.15M | 14.03M | 1.44M | 6.73M |
| Investing Cash Flow | -22.30M | -8.35M | -7.20M | -4.68M | 171.00K | -13.52M | -7.52M | -62.00K | -917.00K | -53.80M | -229.00K | -1.40M | -1.34M | -1.59M | -1.80M | -1.34M | -1.86M |
| Financing Cash Flow | 9.79M | -31.00K | -1.14M | -1.06M | 68.00K | -1.23M | -540.00K | -4.87M | -1.79M | 53.05M | -7.62M | -7.97M | -252.00K | -2.84M | -12.13M | -131.00K | -1.29M |
| Capital Expenditure | - | - | - | - | - | - | - | - | -890.00K | -986.00K | -1.22M | -1.15M | -1.20M | -1.59M | -1.79M | -2.64M | -1.26M |
| Free Cash Flow | - | - | - | - | - | - | - | - | 167.00K | 1.90M | 6.83M | 8.18M | 67.00K | -438.00K | 12.24M | -1.20M | 5.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 48.6% | 47.9% | 46.1% | 47.1% | 45.4% | 45.4% | 44.8% | 46.3% | 50.6% | 52.3% | 55.4% | 56.8% | 56.9% | 53.7% | 58.9% | 58.2% | 57.7% |
| Operating Margin % | 9.4% | 9.4% | 7.7% | 7.0% | 1.5% | 6.1% | -1.6% | -2.9% | -0.8% | 0.8% | 0.3% | 0.2% | 1.7% | -6.1% | 1.7% | -6.6% | -56.1% |
| Net Margin % | 8.4% | 17.6% | 3.5% | 2.1% | -1.7% | 2.2% | -17.5% | -4.1% | -1.1% | -2.4% | -4.0% | -7.6% | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% |
| ROE % | 9.6% | 21.1% | 4.0% | 2.3% | -1.9% | 2.5% | -24.5% | -6.0% | -1.1% | -3.5% | -5.7% | -10.2% | -0.3% | -13.2% | -4.7% | -19.6% | -412.8% |
| ROCE % | - | 9.0% | 7.2% | 6.3% | 1.3% | 5.6% | -1.7% | -3.2% | -0.7% | 0.7% | 0.3% | 0.2% | 1.5% | -5.7% | 1.7% | -8.7% | -83.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Weber Capital Management LLC /ADV | 6.83% | 310.86K | $2.47M |
| 2 | Meros Investment Management, Lp | 4.02% | 182.99K | $1.45M |
| 3 | Acadian Asset Management. LLC | 3.95% | 179.61K | $1.43M |
| 4 | Vanguard Capital Management LLC | 3.73% | 169.62K | $1.35M |
| 5 | Nano Cap New Millennium Growth Fund L P | 3.14% | 143.08K | $1.14M |
| 6 | Corsair Capital Management, L.P. | 2.70% | 122.81K | $976.34K |
| 7 | Two Sigma Investments, LP | 2.52% | 114.55K | $910.63K |
| 8 | Renaissance Technologies, LLC | 2.18% | 99.33K | $789.65K |
| 9 | Blackrock Inc. | 1.36% | 61.83K | $491.58K |
| 10 | Geode Capital Management, LLC | 1.04% | 47.55K | $378.06K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HBIO
(HBIO) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQzAwTW90V3llRExpcVBiRzVReERBeko3Wi1aSDc0NC1aVVRpWWhjMmRDeXRjUHZkTWNLcGd4R1IzY3BrMnlvenh2RzJycTFaWG5ndHJLbm5LeEVJelVVclJLTmRiZkNWTUdOcnROV2tNdktEUTZGdW9aM0c1ekQ2ZVczY1hCTXRKVHlyNC…
HBIO Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1PdGhnV1BzLXBDNlNBOEdhSW5NQUZOV2tia0hrRy1KTThMTlVDdTNnc1pPZGpnVktBcmhLeHVHYlRCemJsRDZXeDNlZ3hyd0FIcDZtcHo1Qms4OFJJWlVSc2ZWYUo2Znl0OUFFaW9NeG4xYjhXYTFsWFdB?oc=5" target="_blank">HBI…
When Should You Buy Harvard Bioscience, Inc. (NASDAQ:HBIO)? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPMVhVdDVGVl9JeElKSk9zaF9DOXJvMkk2UWZCSjV5cTZXalNSdkd1aVE1ZzFWamhPQWxyOUJxeFJGenAyMk5IQ2VSdm5TRmxhN0ViV3hOQi1IOTU1MUFtMGY0amhiVTlYV2wtV1V4TUx1a2Y4cWlwa0dabEd5cVVkMFpiLU9hU2gtREpIYU…
HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNbkUzeTFGT2lvVUc3MS1ZeFp0enhPamw3RUZPbXp2RGNJQTU1cGRVdWkyZ2dCVEIwcjE1NWNMZFdoekxNUDdBZlNTdjVuMmlTa0w5NVNxeW9GNmpDTUF0V2tjd04yeExGajF1RnVQSTJqSzhkaHFQc3U4VHdZNzBOcEs4U3MwcVJaclljND…
Harvard Bioscience to release quarter results before market opens Aug. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOQ3E5SHJZNkRFT3NqeW1RY2RDT3NDRUY1MDNFX2hrM09jVW1GM1I5NlR4RUlTb0RYZ3lTSHBjcHJzRzNGSGVKd2pYb054VUl2UllKU0pwSkJYMTM2a2U4ZHZ1Y1JkOEN0U0tJUUxPZ2cyV2ZzQ3BnaDhTU284aFQtYzNWQkxKUDItUHVobW…
HBIO - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE05UjgxeDBxcTB4QnJQeTdDYzliWUpkdXY3Z0RsZDNtc1BYUjY4ZURrZ3F4R0IyY3o4RF9ZV0w3UEVVTU1IYkE?oc=5" target="_blank">HBIO</a> <font color="#6f6f6f">Finviz</font>…
HBIO — Frequently Asked Questions
What is the current share price of Harvard Bioscience, Inc. (HBIO)?
As of 2026-09-19 21:16 PDT, Harvard Bioscience, Inc. (HBIO) trades at $7.95 on NasdaqCM. Its 52-week range is $3.80 to $8.20.
What is the market capitalisation of HBIO?
Harvard Bioscience, Inc. (HBIO) has a market capitalisation of $36.19M on NasdaqCM.
What is the P/E ratio of HBIO?
HBIO trades at a trailing price-to-earnings (P/E) ratio of -3.46. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.88.
What is the return on equity (ROE) of HBIO?
HBIO has a return on equity (ROE) of -89.95%. Its return on capital employed (ROCE) is -83.60%.
Is HBIO a good stock to buy?
This page provides a data-driven analysis of Harvard Bioscience, Inc. (HBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.